Advertisement

Angiogenesis

, Volume 15, Issue 3, pp 391–407 | Cite as

Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression

  • Hua Zhou
  • Nada O. Binmadi
  • Ying-Hua Yang
  • Patrizia Proia
  • John R. BasileEmail author
Original Paper

Abstract

The semaphorins and plexins comprise a family of cysteine-rich proteins implicated in control of nerve growth and development and regulation of the immune response. Our group and others have found that Semaphorin 4D (SEMA4D) and its receptor, Plexin-B1, play an important role in tumor-induced angiogenesis, with some neoplasms producing SEMA4D in a manner analogous to vascular endothelial growth factor (VEGF) in order to attract Plexin-B1-expressing endothelial cells into the tumor for the purpose of promoting growth and vascularity. While anti-VEGF strategies have been the focus of most angiogenesis inhibition research, such treatment can lead to upregulation of pro-angiogenic factors that can compensate for the loss of VEGF, eventually leading to failure of therapy. Here, we demonstrate that SEMA4D cooperates with VEGF to promote angiogenesis in malignancies and can perform the same function in a setting of VEGF blockade. We also show the potential value of inhibiting SEMA4D/Plexin-B1 signaling as a complementary mechanism to anti-VEGF treatment, particularly in VEGF inhibitor–resistant tumors, suggesting that this may represent a novel treatment for some cancers.

Keywords

Semaphorin 4D Plexin-B1 VEGF Head and neck squamous cell carcinoma Tumor-induced angiogenesis 

Notes

Acknowledgments

The authors would like to thank Ernest Smith and Maurice Zauderer of Vaccinex, Inc., for providing the anti-SEMA4D antibody and offering technical support and Daniel Martin and Silvio Gutkind of the National Institute of Dental and Craniofacial Research, NIH, for contributing the head and neck cancer cell lines and assisting in the generation of shRNA lentiviruses. This work was supported by the National Cancer Institute grant R01-CA133162 to J.R.B.

References

  1. 1.
    Zachary I (2003) Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules. IDrugs 6:224–231PubMedGoogle Scholar
  2. 2.
    Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95:9349–9354PubMedCrossRefGoogle Scholar
  3. 3.
    Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201PubMedCrossRefGoogle Scholar
  4. 4.
    Semenza GL (2001) Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 108:39–40PubMedGoogle Scholar
  5. 5.
    Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463–475PubMedCrossRefGoogle Scholar
  6. 6.
    Kumanogoh A, Kikutani H (2001) The CD100–CD72 interaction: a novel mechanism of immune regulation. Trends Immunol 22:670–676PubMedCrossRefGoogle Scholar
  7. 7.
    Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ (1996) Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci USA 93:11780–11785PubMedCrossRefGoogle Scholar
  8. 8.
    Carmeliet P, Tessier-Lavigne M (2005) Common mechanisms of nerve and blood vessel wiring. Nature 436:193–200PubMedCrossRefGoogle Scholar
  9. 9.
    Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99:59–69PubMedCrossRefGoogle Scholar
  10. 10.
    Torres-Vazquez J, Gitler AD, Fraser SD, Berk JD, Van NP, Fishman MC, Childs S, Epstein JA, Weinstein BM (2004) Semaphorin–plexin signaling guides patterning of the developing vasculature. Dev Cell 7:117–123PubMedCrossRefGoogle Scholar
  11. 11.
    Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki Ji J, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M (2002) Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 99:3657–3662PubMedCrossRefGoogle Scholar
  12. 12.
    Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS (2004) Class IV semaphorins promote angiogenesis by stimulating rho-initiated pathways through plexin-B. Cancer Res 64:5212–5224PubMedCrossRefGoogle Scholar
  13. 13.
    Basile JR, Holmbeck K, Bugge TH, Gutkind JS (2007) MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem 282:6899–6905PubMedCrossRefGoogle Scholar
  14. 14.
    Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, Bussolino F, Giordano S (2005) Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105:4321–4329PubMedCrossRefGoogle Scholar
  15. 15.
    Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC (1995) Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer 61:98–103PubMedCrossRefGoogle Scholar
  16. 16.
    Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227–231PubMedCrossRefGoogle Scholar
  17. 17.
    Hannon GJ, Conklin DS (2004) RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol Biol 257:255–266PubMedGoogle Scholar
  18. 18.
    Basile JR, Castilho RM, Williams VP, Gutkind JS (2006) Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. PNAS 103:9017–9022PubMedCrossRefGoogle Scholar
  19. 19.
    Paddison PJ, Caudy AA, Sachidanandam R, Hannon GJ (2004) Short hairpin activated gene silencing in mammalian cells. Methods Mol Biol 265:85–100PubMedGoogle Scholar
  20. 20.
    Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O’Shaughnessy A, Gnoj L, Scobie K, Chang K, Westbrook T, Cleary M, Sachidanandam R, McCombie WR, Elledge SJ, Hannon GJ (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428:427–431PubMedCrossRefGoogle Scholar
  21. 21.
    Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93:11382–11388PubMedCrossRefGoogle Scholar
  22. 22.
    Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267PubMedCrossRefGoogle Scholar
  23. 23.
    Stone D, Phaneuf M, Sivamurthy N, LoGerfo FW, Quist WC (2002) A biologically active VEGF construct in vitro: implications for bioengineering-improved prosthetic vascular grafts. J Biomed Mater Res 59:160–165PubMedCrossRefGoogle Scholar
  24. 24.
    Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M (2011) RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3 K/Akt pathway. J Biol Chem 286:9097–9106PubMedCrossRefGoogle Scholar
  25. 25.
    Carretero-Ortega J, Walsh CT, Hernandez-Garcia R, Reyes-Cruz G, Brown JH, Vazquez-Prado J (2010) Phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex-1), a guanine nucleotide exchange factor for Rac, mediates angiogenic responses to stromal cell-derived factor-1/chemokine stromal cell derived factor-1 (SDF-1/CXCL-12) linked to Rac activation, endothelial cell migration, and in vitro angiogenesis. Mol Pharmacol 77:435–442PubMedCrossRefGoogle Scholar
  26. 26.
    Mirzapoiazova T, Kolosova I, Usatyuk PV, Natarajan V, Verin AD (2006) Diverse effects of vascular endothelial growth factor on human pulmonary endothelial barrier and migration. Am J Physiol Lung Cell Mol Physiol 291:L718–L724PubMedCrossRefGoogle Scholar
  27. 27.
    Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG (2003) Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 162:1431–1439PubMedCrossRefGoogle Scholar
  28. 28.
    Sahagun G, Moore SA, Fabry Z, Schelper RL, Hart MN (1989) Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am J Pathol 134:1227–1232PubMedGoogle Scholar
  29. 29.
    Laitinen L (1987) Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 19:225–234PubMedCrossRefGoogle Scholar
  30. 30.
    Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS (2004) Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10:4029–4037PubMedCrossRefGoogle Scholar
  31. 31.
    Sun Q, Zhou H, Binmadi NO, Basile JR (2009) Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 284:32066–32074PubMedCrossRefGoogle Scholar
  32. 32.
    Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G (2001) Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol 166:4341–4347PubMedGoogle Scholar
  33. 33.
    Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, Tamagnone L, Wagner DD, Milla ME, Brass LF (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci USA 104:1621–1626PubMedCrossRefGoogle Scholar
  34. 34.
    Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53–67PubMedCrossRefGoogle Scholar
  35. 35.
    Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121PubMedCrossRefGoogle Scholar
  36. 36.
    Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307PubMedCrossRefGoogle Scholar
  37. 37.
    Ferrara N (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21:21–26PubMedCrossRefGoogle Scholar
  38. 38.
    Terman JR, Mao T, Pasterkamp RJ, Yu HH, Kolodkin AL (2002) MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 109:887–900PubMedCrossRefGoogle Scholar
  39. 39.
    Siebold C, Berrow N, Walter TS, Harlos K, Owens RJ, Stuart DI, Terman JR, Kolodkin AL, Pasterkamp RJ, Jones EY (2005) High-resolution structure of the catalytic region of MICAL (molecule interacting with CasL), a multidomain flavoenzyme-signaling molecule. Proc Natl Acad Sci USA 102:16836–16841PubMedCrossRefGoogle Scholar
  40. 40.
    Ventura A, Pelicci PG (2002) Semaphorins: green light for redox signaling? Sci STKE 2002:PE44Google Scholar
  41. 41.
    Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205:1673–1685PubMedCrossRefGoogle Scholar
  42. 42.
    Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15:21–34PubMedCrossRefGoogle Scholar
  43. 43.
    Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139–147PubMedCrossRefGoogle Scholar
  44. 44.
    Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246PubMedCrossRefGoogle Scholar
  45. 45.
    Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRefGoogle Scholar
  46. 46.
    Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H (2012) Neuropilin-1 expression in cancer and development. J Pathol 226:50–60PubMedCrossRefGoogle Scholar
  47. 47.
    Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D (2010) Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9:9PubMedCrossRefGoogle Scholar
  48. 48.
    Mendonca DB, Mendonca G, Aragao FJ, Cooper LF (2011) NF-kappaB suppresses HIF-1alpha response by competing for P300 binding. Biochem Biophys Res Commun 404:997–1003PubMedCrossRefGoogle Scholar
  49. 49.
    Shin DH, Li SH, Yang SW, Lee BL, Lee MK, Park JW (2009) Inhibitor of nuclear factor-kappaB alpha derepresses hypoxia-inducible factor-1 during moderate hypoxia by sequestering factor inhibiting hypoxia-inducible factor from hypoxia-inducible factor 1alpha. FEBS J 276:3470–3480PubMedCrossRefGoogle Scholar
  50. 50.
    Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453:807–811PubMedCrossRefGoogle Scholar
  51. 51.
    van Uden P, Kenneth NS, Webster R, Muller HA, Mudie S, Rocha S (2011) Evolutionary conserved regulation of HIF-1beta by NF-kappaB. PLoS Genet 7:e1001285PubMedCrossRefGoogle Scholar
  52. 52.
    Yang YH, Zhou H, Binmadi NO, Proia P, Basile JR (2011) Plexin-B1 activates NF-kappaB and IL-8 to promote a pro-angiogenic response in endothelial cells. PLoS ONE 6:e25826PubMedCrossRefGoogle Scholar
  53. 53.
    Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4:720–724PubMedCrossRefGoogle Scholar
  54. 54.
    Ch’ng E, Tomita Y, Zhang B, He J, Hoshida Y, Qiu Y, Morii E, Nakamichi I, Hamada K, Ueda T, Aozasa K (2007) Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 110:164–172PubMedCrossRefGoogle Scholar
  55. 55.
    Valente G, Nicotra G, Arrondini M, Castino R, Capparuccia L, Prat M, Kerim S, Tamagnone L, Isidoro C (2009) Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression. Cell Oncol 31:423–436PubMedGoogle Scholar
  56. 56.
    Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, Mazzone M, Comoglio PM, Tamagnone L (2010) Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 120:2684–2698PubMedCrossRefGoogle Scholar
  57. 57.
    Fazzari P, Penachioni J, Gianola S, Rossi F, Eickholt BJ, Maina F, Alexopoulou L, Sottile A, Comoglio PM, Flavell RA, Tamagnone L (2007) Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev Biol 7:55PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Hua Zhou
    • 1
  • Nada O. Binmadi
    • 1
    • 2
  • Ying-Hua Yang
    • 1
  • Patrizia Proia
    • 1
    • 3
  • John R. Basile
    • 1
    • 4
    Email author
  1. 1.Department of Oncology and Diagnostic SciencesUniversity of Maryland Dental SchoolBaltimoreUSA
  2. 2.Department of Oral Basic and Clinical SciencesKing Abdulaziz UniversityJeddahSaudi Arabia
  3. 3.Department of Sports Science (DISMOT)University of PalermoPalermoItaly
  4. 4.Greenebaum Cancer CenterBaltimoreUSA

Personalised recommendations